Hasil Pencarian - M. Cavo

Perbaiki Hasil
  1. 1
    P522: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY

    P522: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY oleh G. Cristiano, J. Nanni, L. Zannoni, C. Sartor, S. Parisi, S. Paolini, C. Papayannidis, M. Cavo, A. Curti

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles

    BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles oleh G. Mazzocchetti, A. Poletti, V. Solli, E. Borsi, M. Martello, I. Vigliotta, S. Armuzzi, B. Taurisano, E. Zamagni, M. Cavo, C. Terragna

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS

    S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS oleh M. Mancini, S. De Santis, C. Monaldi, S. Bruno, F. Castagnetti, G. Gugliotta, A. Iurlo, M. Cerrano, S. Galimberti, S. Balducci, F. Stagno, G. Rosti, M. Cavo, S. Soverini

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

    Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors oleh M. Mancini, S. De Santis, C. Monaldi, L. Bavaro, M. Martelli, F. Castagnetti, G. Gugliotta, G. Rosti, M. A. Santucci, G. Martinelli, M. Cavo, S. Soverini

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P342: BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN

    P342: BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN oleh C. Sartor, I. Vigliotta, V. Robustelli, G. Cristiano, J. Nanni, L. Zannoni, S. Parisi, S. Paolini, G. Marconi, G. Martinelli, A. Curti, M. Cavo, C. Terragna, C. Papayannidis

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

    Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study oleh E. Terpos, A. Symeonidis, S. Delimpasi, E. Zamagni, E. Katodritou, E. Rivolti, M. Kyrtsonis, D. Fotiou, N. Kanellias, M. Migkou, M. Roussou, M. Gavriatopoulou, E. Hatjiharissi, M. Cavo, M. Dimopoulos

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma

    Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma oleh M. Martello, A. Poletti, E. Borsi, V. Solli, L. Dozza, S. Barbato, E. Zamagni, P. Tacchetti, L. Pantani, K. Mancuso, I. Vigliotta, I. Rizzello, S. Rocchi, S. Armuzzi, N. Testoni, G. Marzocchi, G. Martinelli, M. Cavo, C. Terragna

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS

    P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS oleh M. Mancini, C. Monaldi, S. De Santis, C. Papayannidis, M. Rondoni, C. Sartor, S. Bruno, A. Curti, R. Zanotti, M. Bonifacio, L. Scaffidi, L. Pagano, M. Criscuolo, F. Ciceri, C. Elena, P. Tosi, P. Valent, M. Cavo, S. Soverini

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    S174: HIGH LEVEL OF CIRCULATING TUMOUR DNA AT DIAGNOSIS CORRELATES WITH DISEASE SPREADING AND DEFINES MULTIPLE MYELOMA PATIENTS WITH POOR PROGNOSIS

    S174: HIGH LEVEL OF CIRCULATING TUMOUR DNA AT DIAGNOSIS CORRELATES WITH DISEASE SPREADING AND DEFINES MULTIPLE MYELOMA PATIENTS WITH POOR PROGNOSIS oleh M. Martello, A. Poletti, D. Bezzi, E. Borsi, B. Taurisano, V. Solli, S. Armuzzi, I. Vigliotta, G. Mazzocchetti, I. Pistis, L. Pantani, S. Rocchi, K. Mancuso, P. Tacchetti, I. Rizzello, M. Cavo, E. Zamagni, C. Nanni, C. Terragna

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

    PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY M... oleh S. Delimpasi, H. Quach, M. Cavo, P. J. Ho, C. H.-S. Lee, A. Santoro, R. Schots, P. Vlummens, D. H. Yoon, S.-S. Yoon, C. D. Santos, D. Samineni, J. Huang, K. Wehrman, U. Patil, S. Sheikh, M. A. Dimopoulos

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS

    S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS oleh C. Touzeau, A. Krishnan, P. Moreau, A. Perrot, S. Z. Usmani, S. Manier, M. Cavo, C. Martinez-Chamorro, A. Nooka, T. Martin, L. Karlin, X. Leleu, N. Bahlis, B. Besemer, L. Pei, R. Verona, S. Girgis, C. Uhlar, R. Kobos, A. Garfall

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION

    P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION oleh V. Montefusco, A.M. Cafro, G. Margiotta Casaluci, F. Patriarca, R. Mina, M. D’Agostino, A. Capra, C. Priola, B. Dalla Palma, R. Rizzi, A. Genua, M.T. Petrucci, L. Paris, A. Belotti, M. Cavo, C. Conticello, C. Carlo-Stella, M Boccadoro

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

    P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38... oleh M. Offidani, S. Morè, M. Cavo, D. Derudas, F. Di Raimondo, A. Cuneo, L. Baldini, R. Della Pepa, M. Musso, M. Boccadoro, P. Musto, A. Belotti, F. Fioritoni, N. Di Renzo, A. Mele, B. Gamberi, L. De Paoli, R. Zambello, S. Grammatico, M. Brociner, F. Fazio, M. T. Petrucci

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY

    P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY oleh R. Mina, F. Bonello, F. Fazio, R. Saccardi, V. Bongarzoni, F. Marchesi, G. Bertuglia, P. Curci, R. M. Lemoli, S. Ballanti, T. Dentamaro, G. Benevolo, A. Capra, R. Floris, P. Tosi, A. Olivieri, D. Rota-Scalabrini, C. Cangialosi, M. Cavo, P. Corradini, G. Milone, M. Boccadoro, A. Larocca

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

    B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL... oleh P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, S. Giralt

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

    P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA oleh S Usmani, A Alonso, H Quach, Y Koh, A Guenther, CK Min, X Leleu, AO Abdallah, A Oriol, B Bessemer, M Garg, I Sandhu, K Weisel, E Ocio San Miguel, M Cavo, X Zhou, M Kaisermann, L Mis, D Williams, A Yeakey, G Ferron-Brady, D Figueroa, B Kremer, I Gupta, W Janowski

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

    B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS oleh P. Musto, M.C. Minnema, W.W.H. Roeloffzen, A. Capra, B. van der Holt, A. Juul Vangsted, A. Broyl, F. Schjesvold, T. Lund, T. Silkjaer, R. Benjamin, M. Grasso, K. Lung Wu, J. Caers, M. Cavo, R. Hájek, B. Bruno, A. Gadisseur, G. Pietrantuono, M. Offidani, L. Pour, P. Sonneveld, M. Boccadoro, N. van de Donk

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL

    P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED P... oleh A. Larocca, M. D’Agostino, N. Giuliani, E. Antonioli, R. Zambello, S. Ronconi, I. D. Vincelli, F. Ciceri, A. P. Falcone, M. Michieli, F. Cattel, A. Capra, M. Grasso, A. M. Cafro, F. Bonello, R. Floris, M. Offidani, E. Sciorsi, G. Pietrantuono, P. Curci, F. Patriarca, M. Cavo, S. Mangiacavalli, G. Benevolo, A. Evangelista, G. Ciccone, M. Boccadoro, B. Bruno, S. Bringhen

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS

    B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR... oleh N. van de Donk, M.C. Minnema, B. van der Holt, F. Schjesvold, K.L. Wu, A. Capra, A. Broyl, W.W.H. Roeloffzen, A.P.A. Gadisseur, G. Pietrantuono, L. Pour, V. van der Velden, T. Lund, M. Offidani, M. Grasso, L. Giaccone, M. Cavo, T. Silkjaer, J. Caers, S. Zweegman, R. Hajek, R. Benjamin, A. Vangsted, M. Boccadoro, F. Gay, P. Sonneveld, P. Musto

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

    P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA oleh S. Z. Usmani, M. Mielnik, Y. Koh, A. Alonso Alonso, X. Leleu, H. Quach, C.-K. Min, W. Janowski, A.-O. Abdallah, M. Garg, I. Sandhu, E. M. Ocio San Miguel, A. Oriol, P. Rodriquez-Otero, K. Ramasamy, K. Weisel, B. Besemer, M. Cavo, X. L. Zhou, M. C. Kaisermann, C. M. Bego Marques, D. Williams, F. Carreno, B. E. Kremer, I. V. Gupta, M. Hus

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: